We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > BNT162b1

News List

COVID-19 vaccine candidate gets green light for trial in China europeanpharmaceuticalreview
July 16, 2020
The COVID-19 vaccine candidate, BNT162b1, has been approved for clinical trial registration by China’s National Medical Products Administration (NMPA).
FDA grants fast track status to Pfizer and BioNTech Covid-19 vaccines pharmaceutical-technology
July 15, 2020
Pfizer and BioNTech have received fast track designation from the US Food and Drug Administration (FDA) for two of their four potential Covid-19 vaccines.
Pfizer, BioNTech post positive data from study of COVID-19 vaccine candidate expresspharma
July 02, 2020
If studies are successful and mRNA-based vaccine candidate receives regulatory approval, companies expect to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021.